Cargando…
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)
This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic melanoma (28-AJCC stage III, 15-AJCC stage IV), wi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746603/ https://www.ncbi.nlm.nih.gov/pubmed/12085200 http://dx.doi.org/10.1038/sj.bjc.6600251 |
_version_ | 1782172055961075712 |
---|---|
author | Lotem, M Peretz, T Drize, O Gimmon, Z EL, D Ad Weitzen, R Goldberg, H David, I Ben Prus, D Hamburger, T Shiloni, E |
author_facet | Lotem, M Peretz, T Drize, O Gimmon, Z EL, D Ad Weitzen, R Goldberg, H David, I Ben Prus, D Hamburger, T Shiloni, E |
author_sort | Lotem, M |
collection | PubMed |
description | This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic melanoma (28-AJCC stage III, 15-AJCC stage IV), with a median follow up of 34 months (6–62). The treatment consisted of eight doses of a vaccine made of 10–25×10(6) autologous melanoma cells either released from the surgical specimen or grown in cell cultures. Tumour cells were conjugated with hapten dinitrophenyl, mixed with Bacille Calmette Guérin and irradiated to 110 Gy. Both disease free survival and overall survival were found to be correlated with intensity of evolving delayed type hypersensitivity to subcutaneous injection of unmodified melanoma cells. Patients with a delayed type hypersensitivity reaction of ⩾10 mm had a median disease free survival of 17 months (mean 35 months) and a mean overall survival of 63 months (median not reached). In contrast, patients with a negative or weak delayed type hypersensitivity had a median disease free survival of 9 months (relative risk of recurrence=4.5, P=0.001), and a median overall survival of 16 months (relative risk of death=15, P=0.001). Stage III patients with a positive delayed type hypersensitivity reaction had an improved disease free survival of 16 months and a mean overall survival of 38 months, whereas patients with a negative delayed type hypersensitivity had a median disease free survival of 7 months (relative risk=4.5, P=0.02) and a median overall survival of 16 months (relative risk=9.5, P=0.005). The adjuvant administration of autologous melanoma vaccine was associated with improved disease-free and overall survival to selected patients who successfully attained anti-melanoma reactivity as detected by positive delayed type hypersensitivity reactions to unmodified melanoma cells. British Journal of Cancer (2002) 86, 1534–1539. DOI: 10.1038/sj/bjc/6600251 www.bjcancer.com © 2002 Cancer Research UK |
format | Text |
id | pubmed-2746603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27466032009-09-18 Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) Lotem, M Peretz, T Drize, O Gimmon, Z EL, D Ad Weitzen, R Goldberg, H David, I Ben Prus, D Hamburger, T Shiloni, E Br J Cancer Clinical This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic melanoma (28-AJCC stage III, 15-AJCC stage IV), with a median follow up of 34 months (6–62). The treatment consisted of eight doses of a vaccine made of 10–25×10(6) autologous melanoma cells either released from the surgical specimen or grown in cell cultures. Tumour cells were conjugated with hapten dinitrophenyl, mixed with Bacille Calmette Guérin and irradiated to 110 Gy. Both disease free survival and overall survival were found to be correlated with intensity of evolving delayed type hypersensitivity to subcutaneous injection of unmodified melanoma cells. Patients with a delayed type hypersensitivity reaction of ⩾10 mm had a median disease free survival of 17 months (mean 35 months) and a mean overall survival of 63 months (median not reached). In contrast, patients with a negative or weak delayed type hypersensitivity had a median disease free survival of 9 months (relative risk of recurrence=4.5, P=0.001), and a median overall survival of 16 months (relative risk of death=15, P=0.001). Stage III patients with a positive delayed type hypersensitivity reaction had an improved disease free survival of 16 months and a mean overall survival of 38 months, whereas patients with a negative delayed type hypersensitivity had a median disease free survival of 7 months (relative risk=4.5, P=0.02) and a median overall survival of 16 months (relative risk=9.5, P=0.005). The adjuvant administration of autologous melanoma vaccine was associated with improved disease-free and overall survival to selected patients who successfully attained anti-melanoma reactivity as detected by positive delayed type hypersensitivity reactions to unmodified melanoma cells. British Journal of Cancer (2002) 86, 1534–1539. DOI: 10.1038/sj/bjc/6600251 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-20 2002-05-03 /pmc/articles/PMC2746603/ /pubmed/12085200 http://dx.doi.org/10.1038/sj.bjc.6600251 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Lotem, M Peretz, T Drize, O Gimmon, Z EL, D Ad Weitzen, R Goldberg, H David, I Ben Prus, D Hamburger, T Shiloni, E Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) |
title | Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) |
title_full | Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) |
title_fullStr | Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) |
title_full_unstemmed | Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) |
title_short | Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) |
title_sort | autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (ajcc stages iii and iv) |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746603/ https://www.ncbi.nlm.nih.gov/pubmed/12085200 http://dx.doi.org/10.1038/sj.bjc.6600251 |
work_keys_str_mv | AT lotemm autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT peretzt autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT drizeo autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT gimmonz autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT eldad autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT weitzenr autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT goldbergh autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT davidiben autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT prusd autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT hamburgert autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv AT shilonie autologouscellvaccineasapostoperativeadjuvanttreatmentforhighriskmelanomapatientsajccstagesiiiandiv |